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Tumor development and progression is initiated and pro­
pelled by the expression of oncogenes and/or inactivation of 
tumor suppressor genes. Karyotypic alterations in tumor cells 
lead to malignant properties including uncontrolled prolifer­
ation, invasive capability, and metastatic potential. Peptide 
growth factors and their receptors serve as the major molecu­
lar signaling system in orchestrating tumor survival, growth, 
and interactions with the microenvironment. Aberrant ex­
pression of these factors by tumor cells confers growth ad­
vantage and competence for metastasis either by autocrine or 
paracrine mechanisms. In human melanoma, tumor progres­
sion is intimately associated with increasing growth auton­
omy of the malignant cells, perhaps due to the constitutive 
production of multiple growth factors. Among these, basic 
G rowth factors are multifunctional and multitargeted soluble proteins that are important both in cell-to­cell communication and in modulating cellular func­tions such as locomotion, adhesion, proliferation, and differentiation. Studies of the cellular and molec-
ular mechanisms responsible for tumor development and progres­
sion have suggested that the constitutive production of growth fac­
tors and functional perturbations of growth factor receptors in 
tumor cells may be involved [1,2]. The production of autostimula­
tory growth factors may subvert normal growth-regulatory mecha­
nisms and facilitate the acquisition of partial or complete growth 
autonomy, a hallmark of malignant cells [3 - 6]. In addition to auto­
crine growth stimulation, growth factors may modulate the func-
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fibroblast growth factor (bFGF) is consistently expressed in 
cultured melanoma cells, but not in normal melanocytes, and 
it appears to be the main factor produced for autocrine stimu­
lation. In addition, bFGF and other growth factors not appar­
ently involved in autocrine loops are thought to have para­
crine roles in tumor development and progression for 
triggering an inflammatory reaction, initiating angiogenesis 
and fibrous stroma formation, modulating the host immune 
response, and activating proteolytic enzymes produced by 
normal cells. Studies on autocrine and paracrine roles of 
growth factors in melanoma development and progression 
will require models that can account for the complex interac­
tions between normal and malignant cells. ] Invest Dermatol 
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tions of and interactions among normal stromal cells such as fibro­
blasts, endothelial cells, and inflammatory cells, and thus generate a 
microenvironment favorable for tumor growth and invasion. Such 
paracrine effects are especially important for growth factors that are 
secreted by tumor cells but lack an autostimulatory function. 
Recent advances in clinical and histopathologic studies have al­
lowed experimental characterization of the distinct phenotypes of 
melanocytic cells from different stages of tumor progression [7]. 
Human melanoma cells in culture have been shown to express and/ 
or secrete several growth factors that potentially have autocrine or 
paracrine effects. Growth-factor responsiveness and synthesis by 
cultured normal human melanocytes, nevus cells, and primary and 
metastatic melanoma cells reflect the respective stage of tumor pro­
gression better than most other currently known markers [1]. There­
fore, the human melanocytic system has been proposed to be the 
most suitable model for the experimental analysis of both tumor 
progression and tumor-associated changes in growth regulation. 
STAGES AND CHARACTERISTICS OF MELANOMA 
DEVELOPMENT AND PROGRESSION 
Based on clinical and histopathologic studies, Clark and colleagues 
[8,9] proposed five major steps of tumor progression in the human 
melanocytic system, as illustrated in Fig. 1. The common acquired 
nevus composed of nests of mature melanocytes is postulated to 
represent the earliest hyperplastic melanocytic lesion. Increasing 
levels of cytologic and architectural atypias are observed in the sub­
sequent stages of tumor progression. The dysplastic nevus showing 
his�ogenetically aberrant differentiation is thought to be the candi­
date precursor for cutaneous malignant melanoma [10]. The first 
malignant step that can be recognized is the radial growth phase 
(RGP) primary melanoma in which the lesion tends to expand 
outward along the radii of an imperfect circle. Tumor cells in this 
stage are either confined to the epidermis or are locally invasive but 
do not show the capacity for rapid growth or metastasis. In the 
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Figure 1. Tumor progression and differentiation in the human melano­
cytic system. Tumor progression may be sequential, from nevus to dys­
plastic nevus then to malignant melanoma, or occur without intermediate 
steps. Nevus cells may persist in situ or differentiate spontaneously along 
pathways histopathologically defined as a Schwannian differentiation 
and experimentally as fibroblast-like differentiation. Differentiation of 
melanoma cells is rare but may occur along the same pathways. 
vertical growth phase (VGP), melanoma cells expand into the papil­
lary dermis and infiltrate the reticular dermis as well as the subcuta­
neous tissue. This step is highly associated with risk for dissemina­
tion. Metastasis represents the final step of tumor progression. 
Human melanoma may develop from normal melanocytes by a 
stepwise tumor progression pathway as described above or by by­
passing any of these stages. On the other hand, nevi and, occasion­
ally, melanomas may spontaneously regress by differentiating into 
non-malignant cells that are morphologically similar to Schwann's 
cells. 
The availability of cells from sequential steps of tumor develop­
ment and progression in the human melanocytic system offers a 
unique experimental model for the extensive characterization of 
each lesional step and thus an understanding of the mechanism of 
tumor progression and repression. Tables I and II summarize pheno­
typic aspects that distinguish different stages of tumor progression. 
In vitro, the following features are observed as normal melanocytes 
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progress to melanoma: increased roundness and morphologic pleo­
morphism, unlimited lifespan, anchorage-independent growth, tu­
morigenicity in athymic mice, non-random chromosomal abnor­
malities, expression of melanoma-associated antigens, continuous 
growth in growth factor-free medium, and constitutive production 
of multiple growth factors. 
GROWTH REQUIREMENTS AND GROWTH-FACTOR 
INDEPENDENCE OF MELANOMA CELLS 
Analysis of specific growth requirements of cultured melanocytic 
cells through the use of serum-free, chemically defined media has 
led to a profile of growth characteristics of melanocytic cells in 
different stages of tumor progression [6,11]. As shown in Table II, 
the continuous growth of normal cultured melanocytes in W 489 
medium depends on at least four mitogens: insulin or insulin-like 
growth factor (IGF)-I, bFGF, a-melanocyte-stimulating hormone 
(MSH), and the phorbol ester 12-0-tetradecanoyl-phorbol-13-ace­
tate (TPA). Like melanocytes, congenital and common acquired 
nevus cells require insulin (or IGF-I) and a-MSH but have a de­
creased requirement for TPA and bFGF in growth medium. How­
ever, the degree of independence of nevus cells from bFGF is hetero­
geneous [12). Primary melanoma cells require at least insulin or 
IGF-I for continuous proliferation, whereas the majority of meta­
static melanoma cells grow independently of any exogenous mito­
gens. An association between growth-factor independence and in­
vasive phenotype is noted in melanoma cells. Cells selected for 
spontaneous metastasis formation in nude mice grew in vitro more 
rapidly than the parental cells in the absence of exogenous growth 
factors [13]. When primary melanoma cells were selected for 
growth factor independence, they were more invasive in vitro and 
individual selected cell lines were also metastatic in mice [14]. If 
cells were first selected for invasiveness through reconstructed base­
ment membranes and then tested for growth-factor independence, 
they grew also more independently from exogenous growth factors 
than were the parental cells. These findings indicate that human 
melanocytic cells grow in an increasingly autonomous way as they 
progress to a more advanced stage of tumor progression. These 
observations also suggest that the production of endogenous growth 
factors for autocrine growth stimulation underlies the loss of exoge­
nous growth factor requirements by malignant cells. 
GROWTH FACTORS AND RECEPTORS PRODUCED 
AND EXPRESSED BY MELANOMA CELLS 
Melanoma cells produce several growth factors and cytokines con­
stitutively, i.e., without prior stimulation by exogenous mitogens. 
To be considered an autocrine growth stimulus, a growth factor 
Table I. In Vitro Characteristics of Cultured Melanocytic Cells Isolated from Different Stages of Tumor Progression 
Characteristic Normal Melanocytes Nevus Cells Primary Melanoma Cells Metastatic Melanoma Cells 
Morphology Bi- or tripolar Bi- or tripolar Cuboidal or spindle Cuboidal or spindle 
Circularity indeX" 0.18 ± 0.07 0.19 ± 0.09 0.38 ± 0.17 0.28 ±0.11 
Pleomorphism indexb 1.0 1.57 2.46 1.24 
Growth Rate (doubling Newborn foreskin: 2-6 d; 20 h to 14 d, depending 12-48 h; infinite dou- 12-36 h; infinite doublings 
time; no. of doublings) up to 60 doublings. on age of donor; 20- blings 
Adult foreskin; 7 -14 d; 50 doublings 
up to 10 doublings 
Chromosomal Abnor- None None Non-random (chromo- Non-random (chromo-
malities somes #1,6, & 7) somes #1, 5, 7, and 9) 
and random 
Growth in soft agar (% <0.0001% 0.001-3.0% (average: 5-15% 5-70% 
colony-forming effi- 0.9%) 
ciency) 
Tumorigenicity in athy- None None 100% in permanent cell 100% in permanent cell 
mic nude mice lines lines (more rapid than 
primary cells) 
• Circularity index is defined as the deviation from a circle, and is expressed as 4x X areas/perimeter'. The higher the index, the closer the shape of the cultured cells is to a 
perfect circle. 
I Pleomorphism index is defined as the average of the means of 50s of circularity and SOs of projected surface area of nevus and melanoma ce1Is as compared with normal 
melanocytes (index = 1.0). 
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Table D. Growth Requirements and Endogenous Production of Growth Factors in Melanocytic Cells 
Growth Requirements 
Production of 
Growth Factors 
Melanocytes 
lnsuIinJIGF-I 
a-MSH 
bFGF 
TPA 
• Cell growth is less dependent on this factor. 
Nevus Cells 
lnsuIinJIGF-I 
a-MSH 
bFGP' 
TPA 
bFGF 
must meet several experimental criteria: 1) production of the 
growth factor; 2) expression of its receptors; 3) stimulation by exog­
enous growth factor (not always obvious); and 4) inhibition of 
growth by antibodies to specific growth factors or their receptors or 
by antisense oligodeoxynucleotides to inhibit growth-factor synthe­
sis. Most of the growth factors secreted by melanoma cells have been 
tested by these criteria and are discussed below. In addition, growth 
factors produced by melanoma cells may have paracrine effects on 
normal cells in the stroma for either growth stimulation, angiogen­
esis, or motility, and may activate the production of various factors 
by normal cells (Fig 2). However, these interactions are still largely 
hypothetical and require further experimental analysis. 
Basic Fibroblast Growth Factor (bFGF) bFGF was initially 
defined as an activity present in pituitary and brain extracts that 
stimulated the proliferation of mouse 3T3 fibroblasts in vitro 
[15,16]. bFGF is a single polypeptide with 154 amino acids and 
belongs to a family of structural y related proteins including acidic 
FGF, FGF-5, FGF-6, keratinocyte growth factor (KGF), and the 
gene products of the protooncogenes int.2 and K-fgfjhst. The capac­
ity to bind to heparin and related sulfated glycosaminoglycans is a 
distinguishing feature of FGFs. For example, bFGF· is bound to 
heparan sulfate proteoglycan in the extracellar matrix (ECM) where 
it serves as a reservoir for bFGF, and biologically active bFGF can be 
released through degradation of the ECM-bFGF complex by the 
proteolytic enzymes, plasmin or heparanase [17]. Because bFGF 
lacks a signal peptide sequence for extracellular secretion, the mech-
Figure 2. Interactions between melanoma cells and stroma cells for 
growth stimulation, angiogenesis, and motility. Growth factors pr0-
duced by melanoma cells not only stimulate their own growth but also 
act on adjacent stromal cells, such as fibroblasts, endothelial cells, and 
monocytes, by modulating their proliferation, motility, and release of 
various factors relevant to tumor progression, such as IGF-I and scatter 
factor by fibroblasts, proteolytic enzymes by endothelial cells, and oxy­
gen-free radicals by activated monocytes. 
Primary Melanoma Cells 
lnsuIinJIGF-I 
Metastatic Melanoma Cells 
bFGF 
TGF-a 
TGF-p 
PDGF 
IL-la 
IL-6 
IL-8 
MGSA 
anism for its deposition in the ECM remains unclear. bFGF can be 
isolated from a wide variety of cells and tissues [18,19], and it is a 
potent mitogen for various neuroectodermal and mesodermal cells 
bearing specific cell surface receptor systems [20]. Aberrant expres­
sion of bFGF might be related to malignant transformation, the best 
known examples to date being gliomas and melanomas. In the 
human melanocytic system, bFGF appears to be a natural mitogen 
for both normal melanocytes and malignant melanoma cells [21], 
and bFGF is the growth factor most uniformly expressed by mela­
noma cells. The presence of bFGF transcripts and protein has been 
demonstrated in almost all melanoma cell lines tested using bioacti­
vity assays, Western blotting, polymerase chain reaction (PCR) am­
plification of mRNA, Northern blotting and in situ hybridization 
(Table III). As determined by PCR amplification of cDNA from 
mRNA, other FGF members (KGF, int.2, and k-fgfjhst) are also 
expressed in melanoma cell lines [22,23]. In contrast, normal mela­
nocytes do not express either the bFGF gene transcripts or the 
immunoprecipitable protein [23,24]. Using in situ hybridization, 
we detected bFGF messenger ribonucleic acid (mRNA) in com­
pound nevi predominantly in those nevus cells transversing the 
basement membrane zone, and also found bFGF activity in extracts 
of cultured nevus cells [12]. The importance of bFGF in contribut­
ing to tumor progression of human melanomas is demonstrated by 
the suppression of melanoma growth on inhibition of bFGF activity 
by antisense deoxyoligonucleotides or by internalized bFGF-spe­
cific antibodies [24,25]. The induction of bFGF synthesis in a mur­
ine melanocyte line, L- B10.BR, through bFGF-cDNA transfection 
led to autonomous growth and loss of maturation markers (dendrite 
formation, melanin, and melanosome synthesis) in transfected cells. 
However, such cells remained non-tumorigenic in mice, suggesting 
that overexpression of bFGF confers a growth advantage but does 
not induce a completely transformed phenotype in melanocytes 
[26]. 
Beside its role in autocrine growth stimulation in melanoma, 
bFGF can have additional paracrine functions that are essential for 
tumor development and progression. bFGF has potent angiogenic 
properties, and is mitogenic for a variety of cell types including 
keratinocytes, fibroblasts, and endothelial cells [27,28] (Fig 3). In-
4uction of angiogenesis due to endothelial cell activation by bFGF 
and other angiogenic factors is a significant event in supporting 
continuous tumor expansion by facilitating the entry of tumor cells 
into the circulation. It has been proposed that in cutaneous mela­
noma and other solid tumors, tumor growth beyond a critical thick­
ness is angiogenesis dependent [29], and a correlation between an­
giogenesis and metastatic potential has been documented [30]. In 
addition, bFGF activates plasminogen activator (both urokinase and 
tissue types) and the synthesis of collagenase type IV [28,31,32]. 
Such extracellular degenerative enzymes are assumed to participate 
in tumor invasion and dissemination because antibodies specific for 
plasminogen activator and aprotinin (a plasmin inhibitor) can re­
duce the invasive capacity of human melanoma cells into the extra­
cellular matrix [33-35]. 
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Table m. Expression of Growth Factors at mRNA and Protein Levels in Melanoma Cells 
Growth Factor 
bFGF 
KGF 
PDGF-A 
PDGF-B 
TGF-a 
MGSA 
• u. Rodeck, personal communication. 
Positive Cell Lines/ 
Total Cell Lines 
5/5 
19/19 
12/12 
7/8 
18/19 
3/4 
6/16 
15/19 
3/5 
7/8 
1/4 
2/19 
1/5 
5/8 
3/4 
11/17 
18/19 
1/3 
3/4 
18/19 
9/12 
1/4 
10/17 
,!��ether, these findings indicate the diversity of the biologic 
actlV1nes of bFGF and suggest that angiogenesis, stroma formation, 
an.d �crease� proteolytic activity attributed to bFGF play a deter­
numng role m melanoma progression. 
Plat�let.Derived Growth Factor (PDGF) PDGF was initially 
�escnbed as a platelet-derived polypeptide that stimulates prolifera­
tion of cultured fibroblasts and smooth muscle cells. This factor can 
�o induce fibroblast . migration and collagen synthesis, and is a m1to�en for endothehal cells and apparently important in angio­
genes15 [36]. Structurally, PDGF is a dimeric 30-kD glycoprotein 
composed of A .and B chains forming either homodimers (AA or 
BB) or heterodlmers (AB). In humans, the A and B chains share 
about 60% homology in their amino acid sequences, and they are 
encoded by genes located on chromosomes 7 and 22, respectively. 
Two types of PDGF receptors possessing different affinities and 
speci6citi� for the three isoforms ofPDGF have been reported [37]. 
The autocrme role ofPDGF has been suggested by the findings that 
the PDGF-B chain is encoded by the c-sis protooncogene, the nor­
mal counterpart of the v-sis oncogene of simian sarcoma virus 
[38,39], and that neutralizing antibodies against PDGF inhibit 
transformation by v-sis [40]. PDGF can be synthesized by both 
normal �d malignant human cells in vitro. Activated macrophages, 
endothehal cells, and smooth muscle cells might all be sources of 
PDGF, and a number of human malignant cells produce PDGF and 
express the receptors [41-43]. In human melanomas, both PDGF 
mRNA and protein have been demonstrated (Table III). Most of the 
melanoma cell lines tested expressed PDGF-A, whereas a relatively 
small number of cell lines expressed PDGF-B. Only a few cell lines 
expressed. PDGF recepto� �enes at detectable levels [44,45]. In our 
o� studies J44], the addinon of exogenous PDGF or neutralizing 
antisera ag�nst PDGF to human melanoma cells did not affect 
proliferatio�. However, w� canno� exclude the possibility that 
PDGF and Its receptor act m a "pnvate" (intracellular) autocrine 
loop. The paracrine effects ofPDGF in melanoma are still hypothet­
ical (Fig 2). 
MelaD:0?U' Growth 8tb:D:ulatory Activity (MG8A) MGSA 
�as onginally �efine� by Richmond and co-workers [46] as a dis­
tinct growth-snmulanng factor for human melanoma cells in cul­
ture. Puri6cation of this factor revealed an association of MGSA 
Assay for Factor Reference 
Northern blotting 44 
RT-PCR 23 
Western blotting 
In situ hybridization 97 
RT-PCR 23 
Northern blotting 44 
Northern blotting 52 
RT-PCR 23 
Northern blotting and PDGF 45 
Receptor-competing assay 
RNAse protection 98 
Northern blotting 44 
RT-PCR 23 
Jmmunoprecipitation 45 
RNAse protection 98 
Northern blotting 44 
Northern blotting 52 
RT-PCR 23 
Jmmunoprecipitation 
Northern blotting 44 
RT-PCR 23 
Immunoprecipitation and NRI< assay 
Northern blotting 44 
Northern blotting 52 
bioactivity with 13- and 16-kD molecular mass polypeptides. The 
mature form of human MGSA is 73 amino acids long and has se­
quence homology to the gro gene product [47]. Subsequent studies 
showed tha� MGSA is functionally and structural y related to the 
platelet-denved p-thromboglobulin superfamily that includes im­
portant inflammato� mediators: interleukin (IL)-8, macrophage 
inflammatory protem-2, :md
.
neutroph�-activating protein-1 [48]. 
The M�SA receptor, which 15 only partially characterized, appears 
to contam a 35-kD plasma membrane component and 60-kD and 
80-kD cytosolic components, and it copuri6es with several phos­
phorylated proteins. Similarity between the MGSA and IL-8 recep­
tors has been suggested based on the competition of MGSA with 
IL-8 in binding to cells. The .cDNA for the IL-8 receptor has been 
recently cloned and characterIZed as a member of the superfamily of 
receptors that couple to guanine nucleotide-binding proteins 
[49,50]. Immunoreactivity of MGSA has been demonstrated in 
�ost melano� and nevus specimens [51], and cultured melanocy­
tIc cells establ15hed from normal skin, dermal nevi, dysplastic nevi, 
and me!anoma.express M�SA transcripts [52,53]. However, MGSA 
e�presslon vanes depending on the presence of serum in the me­
dium. In serum-free conditions, only low-level MGSA transcri 
tions were detected in one of five melanoma cell lines analyzed 6; 
Nort�em blotting [44]: Similarly, only low-level MGSA gene ex­pressIon was detected In Hs294T melanoma cells maintained in 
serum-free medium [54]. Most cultures of nevus cells in the absence 
of serum express MGSA mRNA, but the protein cannot be detected 
by a MGSA-speci6c monoclonal antibody [53]. 
MGSA has been shown to be mitogenic for normal melanocytes, 
nevus cells, and melanoma cells in vitro [53]. Proliferation of 
MGSA-produc�g Hs294! melanoma cells can be inhibited by a 
monoclonal. antIbody agaInst MGSA, suggesting an autocrine role 
for MGSA In these cells [55]. The role for MGSA in melanoma 
�rogression has .been studied in murine melanocytes. Overexpres­slon of recombInant MGSA by transfection of melan-A murine 
melanocytes with the MGSA gene can transform normal melano­
cytes [56]. MGSA is also produced by a variety of normal and trans­
formed �ells [47,48]. Because the production ofMGSA is inducible 
by a vartety of exogenous mitogens, including IL-1, tumor necrosis 
factor (TNF), PDGF, and MGSA itself [54], it is conceivable that 
the release of MGSA and possibly the related IL-8 in tumor tissue 
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amplifies recruitment and activation of neutrophils and lympho­
cytes [57]. Activated inflammatory cells may degranulate miscella­
neous proteolytic enzymes and produce large quantities of oxygen­
free radicals (Fig 3). Activated oxygen-free radicals, if not properly 
scavenged, are thought to attack chromosomes and subsequently 
increase genetic instability and cellular heterogeneity, which are 
postulated to act as a driving force for tumor development [58]. 
Transforming Growth Factor-p (TGF-fJ) TGF-p is a 25-kD 
dimeric protein that was originally named for its ability to cooperate 
with TGF-a in transforming non-malignant NRK fibroblasts, as 
assayed by their overgrowth in monolayer and formation of colo­
nies in soft agar [59]. Five distinct but closely related TGF-p iso­
forms have been cloned. TGF-p synthesis and expression can be 
identified in a variety of normal and transformed cells of different 
origin. TGF-p exhibits a multitude of functions in cell growth 
regulation, tissue development, cell differentiation and adhesion 
[60]. With respect to cell proliferation, TGF-p appears to be bifunc­
tional, depending on the cell type and the presence of other growth 
factors [61]. TGF-p inhibits cell growth in the majority of normal 
and malignant cells of epithelial, endothelial, and lymphoid origin, 
whereas it stimulates growth of mesenchymal cells. Human mela­
noma cells have been shown to be both a source and a target for 
TGF-p. Several studies demonstrate that TGF-p mRNA is constitu­
tively expressed in melanocyte [23,44] and melanoma cell lines 
(Table III), and TGF-p protein is also released by melanoma cell 
lines. However, the TGF-p released by melanoma cells appears to be 
inactive (U. Rodeck, personal communication). Although TGF-p 
receptors on melanocytic cells have not been well characterized, 
growth of both cultured melanocytes and melanoma cells is inhib­
ited by exogenous active TGF-p [44,61]. In vivo, the significance of 
melanoma-derived TGF-p remains to be investigated. It is possible 
that the activation of TGF-p occurs through enhanced proteolysis 
by plasmin or cathepsin D present in tumor tissue. A negative auto­
crine role for TGF-p in vivo for melanocytic cells of all stages of 
progression is also possible. 
In addition to modulating melanoma cell growth, bioactive 
TGF-p has pleiotropic effects on tumor stromal cells, where it pro­
motes ECM formation [60,62], upregulates the expression of adhe­
sion molecules such as p-integrins and neural cell adhesion molecule 
[63,64], increases the activity for protease inhibitors [65], and inter­
feres with signal transduction of EGF [66]. 
Epidermal Growth Factor {EGF)/Transforming Growth 
Factor-alpha (TGF-a) EGF and TGF-a are two structurally re­
lated polypeptides that compete with each other for binding and 
activation of the EGF receptor. EGF/TGF-a-like activity is pro­
duced by many types of tumor cells, and studies have shown that this 
activity is mainly TGF-a rather than EGF [67]. TGF-a is a 6-kD 
polypeptide first purified and characterized from a human mela­
noma cell line. TGF-a is initially synthesized as a membrane-bound 
precursor with 159 or 160 amino acids. The extracellular domain 
contains the active soluble TGF-a that can be released by proteoly­
tic cleavage [68]. Although normal cells such as keratinocytes can 
produce TGF-a, it is consistently associated with neoplastic trans­
formation. TGF-a is predominantly expressed in human solid 
tumor cells, especially of epithelial cell origin, and many tumors 
also coexpress the EGF receptor, indicating the possible presence of 
TGF-ajEGF receptor autocrine mechanisms in these tumors [69]. 
Autocrine self-stimulation of TGF-a in colorectal, pancreatic, 
breast, and ovarian carcinoma cells has been demonstrated using 
monoclonal antibodies against secreted TGF-a or against the EGF 
receptor [70,71]. 
Exogenous TGF-a has substantial effects on cell growth both in 
vitro and in vivo. TGF-a from the supernatant of melanoma cells can 
stimulate the anchorage-independent growth of fibroblasts and, 
when expressed either by tumor cells or by adjoining keratinocytes, 
can stimulate growth of skin papillomas in vivo [72]. Normal mela­
nocytes in culture, as determined by Northern hybridization and 
PCR eDNA amplification methods, do not express detectable 
TGF-a message unless they are stimulated by ultraviolet radiation 
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(UVR) [73]. In contrast, the majority of melanoma cell lines express 
TGF-a mRNA and protein constitutively (Table III). Expression of 
the EGF receptor in vivo is closely correlated with the stages of 
melanoma progression [74], and melanoma growth in vitro can be 
augmented by exogenous EGF, especially for cells freshly isolated 
from patients [75]. This latter finding suggests an autocrine capacity 
for TGF-a in melanoma cells. However, in our subsequent studies, 
the presence of neutralizing antibodies to human TGF-a or EGF 
receptor in the culture medium failed to inhibit growth of estab­
lished melanoma cell lines that simultaneously expressed both 
TGF-a and EGF receptor [44], implying that the secreted TGF-a, 
like PDGF, does not necessarily function as a direct mitogen for 
melanoma cells in vitro. Although human melanoma cells fre­
quently secrete TGF-a-like factors, the paracrine activities of 
EGF/TGF-a in contributing to melanoma progression are not 
clear. In a transgenic mouse model, overexpression of the TGF-a 
gene is associated with the induction of epithelial hyperplasia, pan­
creatic metaplasia, and carcinoma of the breast [76]. Whether abun­
dant TGF-a in tumor tissue promotes melanoma development and 
progression awaits further study. 
Other Growth Factors Nerve growth factor (NGF) is essential 
for the development and survival of sympathetic and sensory neu­
rons, and acts as a differentiating agent for embryonic adrenal and 
pheochromocytoma cells. Normal epidermal melanocytes exeress 
the 75-kD NGF surface receptor in culture but not in situ [77J. In 
contrast, moderate and high level expression of the NGF receptor 
can be demonstrated in nevus and melanoma cells both in vivo and in 
vitro [77,78]. Although there is a correlation between melanoma 
progression and NGF receptor expression, melanocytic cells neither 
produce NGF nor respond to exogenous NGF. 
Insulin and IGF-I are potent mitogens for a number of cell types. 
Growth of normal melanocytes, nevus cells, and primary melanoma 
cells is enhanced by insulin/IGF-I in vitro. Both factors act through 
the IGF-I receptor [75,79]. IGF-I has also been reported to stimulate 
the motility of a melanoma cell line [80,81]. Although to date there 
is no evidence that melanocytic cells synthesize IGF-I, increased 
production of IGF-I has been observed in fibroblasts by exogenous 
PDGF, which may be released by melanoma cells [82]. Thus, dual 
paracrine interactions involving IGF-I and PDGF expression by 
stromal fibroblasts and melanoma cells can be envisioned. 
Melanoma cells, especially of murine origin, have been known to 
respond to a-MSH by modulating cell proliferation and pigmenta­
tion. In human melanoma cells, a-MSH receptors are expressed in 
various cell lines. Lejeune et al [83] reported the simultaneous pres­
ence of a-MSH immunoreactivity and a-MSH receptors, in a 
human metastatic melanoma cell line. Although human melano­
cytes and nevus cells in culture are consistently growth-stimulated 
by a-MSH, exogenous a-MSH has no apparent effect on cell repli­
cation in most of human melanoma cell lines in vitro [12,84,85]. 
Melanoma cells also produce several cytokines, including IL-1a, 
IL-1P, 1L-6, IL-7, and IL-8, of which IL-1 has been best studied 
[1,86]. Motility factors, notably the autocrine motility factor, is 
produced by melanoma cells [87] (Fig 2). Scatter factor (hepatocyte 
growth factor) released from fibroblasts can stimulate DNA synthe­
sis and growth on human melanocytes [88] possibly �ough the 
activation comet scatter growth factor receptors. However, the roles 
'of any of these cytokines in melanoma development and progres­
sion are not clear. 
ULTRAVIOLET LIGHT AND PARACRlNE 
REGULATION OF PRIMARY MELANOMA CELLS 
Due to their widespread expression in human tissues, growth factors 
released by keratinocytes, fibroblasts, endothelial cells, platelets, 
and lymphocytes in the vicinity of a primary cutaneous melanoma 
lesion may affect growth of the malignant cells. Expression of 
growth factors in normal cells is inducible in response to miscella­
neous internal and environmental stimuli. Solar irradiation, espe­
cially in the UVB range, has been long speculated to be a risk factor 
for the development and progression of human cutaneous mela-
VOL. 100, NO. 2, SUPPLEMENT, FEBRUARY 1993 
noma [89], and UVR has been shown to have various biologic 
effects on mammalian cells. Disturbed growth factor networks have 
been suggested in UV irradiated human skin. In vitro studies reveal 
that UVR induces the expression of TGF-a by melanocytes [73], 
synthesis ofbFGF, IL-1, and IL-6 in keratinocytes [21,90,91], pro­
duction of IGF-I by keratinocytes and Langerhans cells [92], expres­
sion ofNGF receptor on melanocytes [93], and increased activity of 
the melanotropin receptor in melanoma cells [94]. These findings, 
together with the evidence that UVR at an appropriate dosage is an 
independent mitogen for melanocytic cells [95], suggest that both 
normal melanocytes and melanoma cells from early primary lesions 
can be direct or indirect targets for UVR. It is possible, but has not 
yet been e.xperimentally demonstrated, that exaggerated expression 
of growth factors and receptors in primary melanocytic lesions are 
involved in UVR-mediated melanoma development and progres­
SIon. 
CONCLUSION 
Distinct biologic features characterizing each stage of tumor pro­
gression in the melanocytic cell system have been defined. Less 
stringent growth requirements and constitutive production of en­
dogenous growth peptides are two prominent features in melanoma 
development and progression. In addition to TGF-p and MGSA, 
which can also be produced by normal melanocytes, melanoma cells 
in culture specifically and constitutively express bFGF, TGF-a, 
PDGF A and B chains, and interleukins. The growth-factor inde­
pendence of melanoma cells might well be the result of the auto­
crine stimulation by one or several endogenous factors. bFGF is the 
best characterized candidate for autocrine stimulation in melanoma 
cells, whereas the autocrine role for other growth factors remains to 
be evaluated. 
In light of the pleiotropic dimensions of peptide growth factors, it 
seems reasonable to expect that factors derived from tumor cells or 
from adjacent epidermal and dermal cells on stimulation (such as 
UVR) would modulate each other in a paracrine manner and partici­
pate in the processes of angiogenesis, extracellular matrix forma­
tion, and proteolytic processes to facilitate tumor growth and inva­
sion. However, little experimental evidence for paracrine effects of 
tumor-derived growth factors exists yet. This is partly due to the 
limitations of current experimental models, but more importantly, 
to the complexity of interactions among different cell types and 
their microenvironments, which make it difficult to extrapolate 
from in vitro studies of the contribution of paracrine growth factors 
to tumor progression in humans. Given these constraints, recent 
advances in the development of skin equivalent models containing 
epidermal and dermal components hold promise in elucidating 
some of the complex interactions between cells [96]' A better knowl­
edge of the roles of various peptide growth factors in regulating cell 
phenotypes and growth will yield new insights into the pathogene­
sis of melanoma development and progression, and will likely pro­
vide a framework for a future biologic approach to the diagnosis and 
therapy of human cutaneous melanoma. 
Work from this laboratory was supported in part by grants CA-25874, CA-44877, 
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